The goal of treatment for hypereosinophilic syndrome is to reduce the numbers of eosinophils in your body and prevent tissue damage, especially to your heart. Your treatment depends on your symptoms, the severity of your condition and the cause of your HES.
April 28, 2015
- Watchful waiting. If you have no symptoms and your eosinophil count is low enough, your doctor may opt for a "wait and see" approach. Your condition will then be closely monitored for any changes related to HES.
- Prednisone. Generally, if you don't have the FIP1L1-PDGFRA gene mutation, you'll initially be treated with prednisone, a corticosteroid, which is gradually tapered to the lowest dose that controls the eosinophil count. If a high dose of prednisone is needed, steroid-sparing medications are added to avoid the side effects. Prednisone side effects may include mood swings, high blood pressure and increased risk of infections.
- Protein-tyrosine kinase inhibitor. If you have the FIP1L1-PDGFRA gene mutation, you have, by definition, chronic eosinophilic leukemia. You'll need treatment with imatinib mesylate (Gleevec), a type of drug known as a protein-tyrosine kinase inhibitor. Imatinib mesylate slows the growth of cancer cells and is almost 100 percent effective, especially for men.
- Hypereosinophilic syndrome (HES). American Academy of Allergy, Asthma and Immunology. http://www.aaaai.org/conditions-and-treatments/related-conditions/hypereosinophilic-syndrome.aspx. Accessed Jan. 29, 2015.
- AskMayoExpert. What is the definition of the hypereosinophilic syndrome? Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Eosinophilia. The Merck Manual Professional Edition. http://www.merckmanuals.com/professional/hematology_and_oncology/eosinophilic_disorders/hyper eosinophilic_syndrome.html. Accessed Jan. 29, 2015.
- Roufosse F, et al. Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes. http://www.uptodate.com/home. Jan. 29, 2015.
- Roufosse F, et al. Treatment of the hypereosinophilic syndromes. http://www.uptodate.com/home. Jan. 29, 2015.
- Gotlib J. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. American Journal of Hematology. 2014; 89:325-37.
- Golden AK. Decision Support System. Mayo Clinic, Rochester, Minn. Feb.12, 2015.
- Kita, H. Alternaria and ribonucleases in Th2-type immunity. National Institutes of Health. http://projectreporter.nih.gov/. Accessed March 17, 2015.